Rhinomed (ASX:RNO) Interest Expense : A$-0.29 Mil (TTM As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Rhinomed Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Rhinomed's interest expense for the six months ended in Jun. 2023 was A$ -0.22 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was A$-0.29 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Rhinomed's Operating Income for the six months ended in Jun. 2023 was A$ -3.95 Mil. Rhinomed's Interest Expense for the six months ended in Jun. 2023 was A$ -0.22 Mil. Rhinomed did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Rhinomed Interest Expense Historical Data

The historical data trend for Rhinomed's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhinomed Interest Expense Chart

Rhinomed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Interest Expense

Get a 7-Day Free Trial

-0.04

-0.29

Rhinomed Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Interest Expense	Get a 7-Day Free Trial															-0.04	-0.02	-0.02	-0.07	-0.22

Rhinomed Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.29 Mil.

Rhinomed (ASX:RNO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Rhinomed's Interest Expense for the six months ended in Jun. 2023 was A$-0.22 Mil. Its Operating Income for the six months ended in Jun. 2023 was A$-3.95 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2023 was A$0.02 Mil.

Rhinomed's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Rhinomed did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Rhinomed (ASX:RNO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rhinomed Ltd (ASX:RNO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

RHNMF:USA

Address

132 Gwynne Street, Level 1, Cremorne, VIC, AUS, 3121

Website

https://www.rhinomed.global

Rhinomed Ltd is a medical technology company, with a patented nasal technology platform. It is engaged in the research, development and commercialization of consumer and medical devices including nasal, respiratory and nasal drug delivery technologies. It operates in one segment which is the identification, acquisition, and commercialization of late-stage consumer therapeutic and medical delivery technologies. The products of the company involve Rhinoswab, Mute, Turbine and Rhinoswab Junior. It operates geographically within North, Central, and South America, Asia-Pacific, Europe, Middle East, and Africa. The company earns majority of its revenue from Asia-Pacific.

Rhinomed (ASX:RNO) Headlines

No Headlines